Show simple item record

dc.contributor.authorKohlhoff, Stephan A
dc.contributor.authorHuband, Michael D
dc.contributor.authorHammerschlag, Margaret R
dc.date.accessioned2023-07-05T18:46:44Z
dc.date.available2023-07-05T18:46:44Z
dc.date.issued2014-12
dc.identifier.citationKohlhoff SA, Huband MD, Hammerschlag MR. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 2014 Dec;58(12):7595-6. doi: 10.1128/AAC.03920-14. Epub 2014 Oct 6. PMID: 25288086; PMCID: PMC4249501.en_US
dc.identifier.eissn1098-6596
dc.identifier.doi10.1128/AAC.03920-14
dc.identifier.pmid25288086
dc.identifier.urihttp://hdl.handle.net/20.500.12648/10391
dc.description.abstractThe in vitro activities of AZD0914, levofloxacin, azithromycin, and doxycycline against 10 isolates each of Chlamydia trachomatis and Chlamydia pneumoniae were tested. For AZD0914, the MIC90s for C. trachomatis and C. pneumoniae were 0.25 μg/ml (range, 0.06 to 0.5 μg/ml) and 1 μg/ml (range, 0.25 to 1 μg/ml), respectively, and the minimal bactericidal concentrations at which 90% of the isolates were killed (MBC90s) were 0.5 μg/ml for C. trachomatis (range, 0.125 to 1 μg/ml) and 2 μg/ml for C. pneumoniae (range, 0.5 to 2 μg/ml).
dc.language.isoenen_US
dc.relation.urlhttps://journals.asm.org/doi/epub/10.1128/aac.03920-14en_US
dc.rightsCopyright © 2014, American Society for Microbiology. All Rights Reserved.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleIn vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleAntimicrobial agents and chemotherapyen_US
dc.source.volume58
dc.source.issue12
dc.source.beginpage7595
dc.source.endpage6
dc.source.countryUnited States
dc.description.versionVoRen_US
refterms.dateFOA2023-07-05T18:46:46Z
html.description.abstractThe in vitro activities of AZD0914, levofloxacin, azithromycin, and doxycycline against 10 isolates each of Chlamydia trachomatis and Chlamydia pneumoniae were tested. For AZD0914, the MIC90s for C. trachomatis and C. pneumoniae were 0.25 μg/ml (range, 0.06 to 0.5 μg/ml) and 1 μg/ml (range, 0.25 to 1 μg/ml), respectively, and the minimal bactericidal concentrations at which 90% of the isolates were killed (MBC90s) were 0.5 μg/ml for C. trachomatis (range, 0.125 to 1 μg/ml) and 2 μg/ml for C. pneumoniae (range, 0.5 to 2 μg/ml).
dc.description.institutionSUNY Downstateen_US
dc.description.departmentPediatricsen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalAntimicrobial agents and chemotherapy
dc.identifier.issue12en_US


Files in this item

Thumbnail
Name:
aac.03920-14.pdf
Size:
88.86Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2014, American Society for Microbiology. All Rights Reserved.
Except where otherwise noted, this item's license is described as Copyright © 2014, American Society for Microbiology. All Rights Reserved.